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Abstract
Background: Gaucher disease is caused by defective glucocerebrosidase activity and the consequent accumulation
of glucosylceramide. The pathogenic pathways resulting from lipid laden macrophages (Gaucher cells) in visceral
organs and their abnormal functions are obscure.
Results: To elucidate this pathogenic pathway, developmental global gene expression analyses were conducted in
distinct Gba1 point-mutated mice (V394L/V394L and D409 V/null). About 0.9 to 3% of genes had altered expression
patterns (≥ ± 1.8 fold change), representing several categories, but particularly macrophage activation and immune
response genes. Time course analyses (12 to 28 wk) of INFg-regulated pro-inflammatory (13) and IL-4-regulated
anti-inflammatory (11) cytokine/mediator networks showed tissue differential profiles in the lung and liver of the
Gba1 mutant mice, implying that the lipid-storage macrophages were not functionally inert. The time course
alterations of the INFg and IL-4 pathways were similar, but varied in degree in these tissues and with the Gba1
mutation.
Conclusions: Biochemical and pathological analyses demonstrated direct relationships between the degree of
tissue glucosylceramides and the gene expression profile alterations. These analyses implicate IFNg-regulated pro-
inflammatory and IL-4-regulated anti-inflammatory networks in differential disease progression with implications for
understanding the Gaucher disease course and pathophysiology.
Background
Gaucher disease, an autosomal recessive disorder, is a
common lysosomal storage disease. Insufficient activity
of acid b-glucosidase (glucocerebrosidase, GCase, E.
C.3.2.1.45) in all cells leads to the substrate accumula-
tion including glucosylceramide and glucosylsphingo-
sine, and the various clinical phenotypes. The pathologic
hallmark of Gaucher disease is the presence of lipid
laden macrophages, a.k.a., Gaucher cells, in visceral
organs [1]. The macrophages are thought to be the pri-
mary visceral cells involved in all variants, and these
cells become progressively numerous and engorged with
glucosylceramide by phagocytic processes. By yet unde-
fined mechanisms, this process leads to tissue dysfunc-
tion that can result in fibrosis and scarring during the
later stages of the disease.
Some of these tissue changes have been attributed to
“activation” of the engorged macrophages with subse-
quent release of inflammatory agents. Indeed, some
Gaucher disease patients had increased levels of pro-
inflammatory (i.e., TNFa,I L - 6 ,I L - 8 ,a n dI L - 1 b)a n d
anti-inflammatory cytokines (i.e., CD14) in serum and/
or tissues [2-4]. TNFa production has been suggested as
a response to glucosylceramide accumulation in Gau-
cher disease patients [2]. Serum levels of M-CSF, sCD14
(a macrophage activation marker), and IL-8 can also be
increased and correlations have been made with the
severity of Gaucher disease [3]. An in situ study of
spleen from a Gaucher disease patient showed increased
expression of anti-inflammatory mediators in macro-
phages, including CCL18, CD163, chitotriosidase, IL-
1Ra, and CD14 [5]. Such anti-inflammatory mediators
are considered markers of alternatively activated macro-
phages (aam)[ 6 - 1 0 ]a n di m p l i c a t es e c r e t e dc y t o k i n e s
as pathophysiological agents in Gaucher disease. Such
studies also suggest a central role of glucosylceramide
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ease pathogenesis.
How the insufficiency of GCase activity and the subse-
quent metabolic disturbances related to glucosylcera-
mide and other sphingolipids (GSLs) could lead to such
inflammatory imbalances remains obscure. However, the
consequent imbalances of ceramide, sphingosine, and
sphingosine 1-phosphate in Gaucher disease could affect
immunologic responses, inflammation and cell prolifera-
tion [11-13]. These and other studies implicate profound
systematic pathophysiological changes rather than sim-
ple lipid accumulation as the basis of the disease [1].
The pathologic manifestations of various organs suggest
that the defective glucosylceramide hydrolysis and sub-
strate accumulation in multiple organs affects numerous
metabolic networks. Consequently, systematic transcrip-
tome analyses could provide useful insights into the
resultant molecular events underlying GCase deficiency
and glucosylceramide storage as well as related tissue
pathogenesis in Gaucher disease. In addition to visceral
processes, some correlations of neuropathologic involve-
ment with gene expression profiles in brains from neu-
ronopathic Gaucher disease patients or Gba1 variant
mice [14,15] provide isolated cross-sectional views of
the disease processes. However, they have not provided
insight into the dynamic or sequential nature of such
pathophysiological progression.
Here, viable Gba1 point-mutated mice, V394L/V394L
( 4 L )a n dD 4 0 9V / n u l l( 9V / n u l l ) ,w e r eu s e dt o
explore the temporal and spatial profiles of tissue and
Gba1 mutation-related gene expression by genome-
wide mRNA microarrays and immunohistochemical
analyses. Particular focus was on macrophage activa-
tion (classic and alternative) responses and IFNg
regulated pro-inflammatory or IL-4 regulated anti-
inflammatory networks. These studies established a
starting point for understanding the basis of the
progressive pathophysiology in Gaucher disease at a
molecular/tissue level.
Results
Phenotype of Gba1 V394L homozygotes (4L) and D409 V/
null (9 V/null) mice
4L or 9 V/null mice appear phenotypically normal and
have survived ~ 2 years. All mice have grossly normal
behavior, reproduce, and show no gross evidence of CNS
abnormalities. The residual GCase activity levels in visceral
organs were 6-7% or 4-7% of WT in 4L or 9 V/null,
respectively [16]. By LC-MS/MS analyses, accumulations
of glucosylceramide were detected in 9 V/null lung and
liver as early as at 4 wk (2- to 6-fold over the WT con-
trols), and then progressed up to 33-fold during 12 to 28
wk and >40-fold at 52 wk (Figure 1). In 4L mice, glucosyl-
ceramide levels in lung and liver were 2- to 3-fold
increased at 4 or 52 wk, respectively (Figure 1). Numerous
large storage cells were observed in 9 V/null lungs (Figure
2) and to a lesser extent in liver at 12, 18, and 28 wk. Such
cells were much smaller and less numerous in 4L lungs
(Figure 2). The macrophage nature of storage cells was
evidenced by their CD68 and F4/80 positivity (Figure 2).
Differential gene expression in tissues from Gaucher mice
The RNA samples were from lungs and livers of 9 V/null
and 4L mice at the ages of 4-, 12-, 18- and 28-wk. The
probe sets for each gene in the mutant mice that showed
significantly differential expression were compared with
those from the strain background matched WT. In these
mutant models, the altered probe signals ranged from
560 to 1806 of the 45101 total probes on the chip. For
further analyses, the genes were assigned to the probe
sets. At a false positive rate (FDR) of 0.01, about 1.2-4%
of total genes were significantly differentially expressed:
Figure 1 Glucosylceramide in 9 V/null and 4L mice. A: LC-MS/MS analyses showed an age dependent progressive accumulation of
glucosylceramide in the lung of 9 V/null mice: 6-fold, 28- to 33-fold, and 40-fold greater than WT at 4, 12-28, and 52 wk, respectively. In the 4L
lung, there was ~3-fold increase by 4 to 52 wk. B: Similar, progressive accumulation of liver glucosylceramide: 5-fold, 15-fold, 32-fold, and 46-fold
greater than WT at 12, 18, 28, or 52 wk, respectively. Glucosylceramide levels in the liver of 4L were 2-fold increased over the WT.
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Page 2 of 231171 or 402 genes in lung or liver, respectively, of 9 V/
null mice; 1375 or 406 genes were in lung or liver,
respectively, of 4L mice (Additional file 1). The differen-
tially expressed genes in each tissue were segregated into
12 major functional groups with statistical significance
across the two tissues in both mouse models to provide
global profiles of gene expression. The functional cate-
gories include catalytic activity, cell death, cytoskeleton,
immune response, intracellular signaling cascade, kinase
activity, lipid metabolic process, lysosome, macrophage
activation, response to stress, transcription, and transport
(Table 1 and Additional file 2). In lung, both mouse
models showed similar spectra of gene expression pat-
terns for these functional groups, except genes for
immune response and macrophage activation that were
more highly altered in 9 V/null mice. In 9 V/null and 4L
livers, fewer functional groups (6 to 7) were significant in
comparison with lung profiles (Table 1). Interestingly,
genes for cell death did not reach significance in 4L liver,
and genes for immune response were significant only in
9V/null lung (Table 1). The macrophage activation genes
were grouped as a functional category, because the
macrophage is the hallmark of Gaucher disease, and large
numbers of storage cells (macrophages) were observed
in the lungs of 12-, 18-, and 28-wk old 9 V/null mice
( F i g u r e2 ) .T h ee n r i c h m e n to fd i f f e r e n t i a l l ye x p r e s s e d
gene categories was examined by comparing the percen-
tage populating the various gene ontologies in these two
mouse models across lung and liver from all time points.
Among these 12 different functional categories, the com-
position of macrophage activation genes in 9 V/null lung
was 10% of the total altered genes, and 6% in 4L lung:
these represent 1.7-fold enrichment (Table 1). To corre-
late the gene functional category with their expression
profile in Gba1 mutant mice, the 1171 significantly differ-
entially expressed genes in 9 V/null lung were analyzed
Figure 2 Histology and immunohistology of lung from WT, 4L, and 9 V/null mice. Lung sections were from 28-wk age-matched mice.
Representative H&E sections showed no storage cells in the alveolar spaces of WT or 4L lungs, whereas abundant large storage cells were
present in 9 V/null lung (e.g., arrows). Immunohistochemistry staining with CD68 and F4/80 antibodies showed large positively-staining storage
cells in 9 V/null lung (e.g., arrows), i.e., macrophage origin. In comparison, 4L lung had a few, small CD68 and F4/80 positive cells (e.g., arrows).
WT lungs did not exhibit positive-staining cells. The scale bars are 20 μm. Magnification = 400x.
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revealed across all ages in the lung. Cluster 1 showed 407
genes with low expression (35% of total 1171 genes) in 9
V/null and 4L lung across the 4- to 28-wk age range
when compared with the WT lung (Figure 3, cluster 1).
These down-regulated genes were mainly in the func-
tional categories of catalytic activity, cell death, intracellu-
lar signaling cascade, kinase activity, macrophage, and
transcription (Additional file 3). Cluster 2 contained
about 55% of genes (647 from total 1171 genes) and
showed differential degrees of up-regulation in the 9 V/
null and 4L lung (Figure 3, cluster 2). Cluster 3 showed
10% of genes (117 from total 1171 genes) with high
expression levels exclusively in 9 V/null lung (Figure 3,
cluster 3). These same genes did not have distinct pat-
terns in the 9 V/null liver or the 4L lung and liver data
sets (Figure 3, right panel). Two-dimensional hierarchical
cluster analyses show mutation-type (4L lung vs. 9 V/null
lung) and tissue type-related (lung vs. liver) global gene
expression profiles. These highly expressed 117 unique
genes in 9 V/null lung contained 40 that were macro-
phage activation genes. The others represented intracellu-
lar signaling (5), lipid metabolic process (9), catalytic
activity (23), and transport (10) (Figure 4). These initial
findings strongly indicated the involvement of macro-
phage activation genes in Gaucher disease and led to the
focus on the expression profiles of macrophage activation
related genes in 9 V/null lung.
Expression profile of macrophage activation genes
To explore the expression profile of macrophage activa-
tion, all 119 such genes (Table 1) were analyzed. At
early stages of the disease (4 wk), 44% of these genes
(53/119) were significantly altered with 42 up- and 11
down-regulated in the 9 V/null lung (Additional file 4).
As the disease progressed (12, 18 or 28 wk), 81% (96/
119) of the macrophage activation genes were signifi-
cantly and consistently up-regulated, and 15% (18/119)
of these genes were down regulated in 9 V/null lung
(Additional file 4). The genes with expressions signifi-
cantly changed at 2 or 3 time points from 4 to 28 wk
were considered as consistently affected. Similar expres-
sion profiles were defined in 4L lung where 88% (73/83)
of such genes were altered at 4 wk with 48 up-regulated
and 25 down-regulated. From 12 to 28 wk, 84% (70/83)
of the macrophage activation genes were affected with
43 up- and 27 down-regulated. The mean fold-change
of these consistently up-regulated macrophage activation
genes was >3.5-fold in 9 V/null lung and liver, whereas
a 2.3-fold change was observed in the corresponding 4L
tissues (Figure 5 and Additional file 4).
Using the Ingenuity Analysis System and additional
literature sources [5,8], 9 IFNg-regulated pro-inflamma-
tory and 9 IL-4-regulated anti-inflammatory genes were
significantly expressed (fold change ≥ ±1 . 8 )f r o m1 2t o
28 wk (Table 2) in 9 V/null lungs with 5 pro-inflam-
matory genes significantly altered beginning at 4 wk
(Table 2). Most of these genes were cytokines/chemo-
kines or their receptors, including CCL2, CCL3, CCL6,
CCL9, CCL19, CXCL1, and CXCL12. Other genes
included CD44 (a transmembrane glycoprotein related
to cellular adhesion and migration) and the macro-
phage scavenger receptor 1 (Msr1). Several pro-inflam-
matory genes [IFNg, interleukin 6 (IL-6), inducible
nitric oxide synthase (NOS2) and TNFa] did not meet
the statistical significance (Bold genes in Table 2).
Table 1 Classification of significantly expressed genes in tissues of 9 V/null and 4L mice
Categories Lung Liver
9 V/null 4L 9 V/null 4L
No. % p-value No. % p-value No. % p-value No. % p-value
catalytic activity 440 38% 1.49E-06 527 39% 4.24E-09 160 40% 3.37E-04 157 39% 2.61E-03
intracellular signaling cascade 136 12% 7.49E-10 166 12% 2.40E-10 50 13% 7.50E-04 46 11% 1.24E-03
kinase activity 87 8% 8.41E-04 98 7% 1.41E-03 34 9% 8.07E-03 31 7% 4.46E-02
lipid metabolic process 66 6% 7.62E-04 73 5% 1.43E-02 37 9% 1.22E-05 30 7% 7.71E-04
macrophage activation 119 10% 4.50E-04 83 6% 3.29E-03 24 6% 5.74E-03 26 6% 6.93E-03
transcription 195 17% 1.44E-03 276 20% 2.33E-08 83 21% 2.50E-03 76 19% 4.17E-03
cell death 75 7% 1.36E-04 89 7% 3.83E-04 27 7% 4.93E-02
cytoskeleton 78 7% 3.92E-02 87 7% 5.96E-03
lysosome 29 3% 1.91E-05 27 2% 1.43E-03
response to stress 79 7% 1.52E-03 91 7% 1.20E-02
transport 219 19% 2.14E-04 255 19% 8.03E-03
immune response 54 5% 4.68E-03
The functional categories with p-value < 0.05 were considered significant by Fisher Exact Test.
No. = number of genes.
The empty rows were not significant (p > 0.05).
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lyses were conducted and the lipid-laden macrophages
showed antibody positive signals (see below). The
results show high expression of these four cytokine
proteins in macrophages even though their respective
RNA levels were relatively unchanged. Additional
immunohistochemical analyses showed consistent posi-
tivity with antibodies to CCL2, CCL3, and CCL9; this
was concordant with their RNA expression. Similar
mRNA analyses showed that 6% of altered genes were
in the macrophage activation category in 9 V/null liver
or 4L lung and liver. However, none were pro-inflam-
matory genes (Table 2 and Additional file 5). These
data support disease progression and tissue-type
related profiles of pro-inflammatory gene expression in
Gaucher disease.
Figure 3 Hierarchical cluster analyses of differentially expressed genes in lung and liver of Gba1 mutant mice. The two-dimensional
hierarchical clustering charts include 1171 genes differentially expressed in 9 V/null lung, and the corresponding genes in 9 V/null liver, and
those in 4L or WT lung and liver at ages of 4-, 12-, 18-, or 28-wk (see Materials and Methods). The expression patterns of duplicate chip data are
displayed in adjunct lanes for each transcript. The heat map (Pearson correlation) displays gene group correlation patterns across all time points.
Each column represents the general expression profile of 1171 genes at a time point. Each row represents a single gene across all time points.
The intensities (red to green scale bar) are the log ratios, log2(D/C), where D and C are the gene expression levels in the samples from Gba1
mutant mice and WT controls, respectively, and indicate up- or down-regulated RNA expression. Clustering was performed by distance
measurements. In cluster 1 are the 407 genes down-regulated in 9 V/null and 4L lung compared to the corresponding genes in WT lung (genes
listed in Additional file 2). In cluster 2 are the 647 genes had a variable degrees of up-regulation compared with WT controls. In cluster 3
(orange rectangle) is a group of 117 genes consistently up-regulated in the lung of 9 V/null mice at ages of 12- to 28-wk. These include 40
macrophage activation genes (see Figure 4).
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Page 5 of 23Figure 4 Group 3 over expressed genes in 9 V/null. Two-dimensional hierarchical cluster analyses of the 117 genes in cluster 3 (Figure 3)
from 9 V/null lung showed high expression at ages of 12-, 18-, or 28-wk compared with the genes in 4L and WT lungs. Among these 117
genes, 40 were macrophage activation genes and included 13 pro-/anti-inflammatory pathway genes. The name of each gene is listed and their
major functional categories are presented at the right: macrophage activation related (red), intracellular signaling (blue), lipid metabolic process
(green), catalytic activity (brown), transport (grey), and others (black). The expression level of each gene at different time points is coded
according to the color scale.
Xu et al. BMC Genomics 2011, 12:20
http://www.biomedcentral.com/1471-2164/12/20
Page 6 of 23In the IL-4 regulated pathway, 9 anti-inflammatory
genes were up regulated in 9 V/null lung (Table 2). Two
genes (Igh-6 and Rentla) were up regulated by 4 wk and
then continuously up regulated at 12 to 28 wk. The
other seven anti-inflammatory genes were unchanged at
4 wk. These less significant changes in the anti-inflam-
matory genes at the age of 4-wk reflect the underdeve-
lopment of alternatively activated macrophage features.
With age (12-, 18- or 28-wk), all anti-inflammatory
genes were consistently up regulated including the
NOS2 counteracting enzyme arginase type II (Arg2),
cytokine/chemokine CCL17/CCL22, immunoglobulin
heavy chain 6 (Igh-6), IL-1 receptor antagonist (IL-1rn),
and matrix metallopeptidase MMP9/12/19 (Table 2).
Among these genes, MMP12 expression was exception-
ally high (37- to 56-fold increased). MMP-12, macro-
phage elastase, functions to degrade extracellular matrix
components, e.g., elastin, and is involved in acute and
chronic pulmonary inflammatory diseases associated
with an intense airway remodeling [17,18]. The anti-
inflammatory genes, e.g., IL-4, and the macrophage
scavenger receptor CD163 did not meet statistical signifi-
cance, but were positive by immunohistochemistry. With
9 V/null liver mRNA, only three anti-inflammatory genes
(Igh-6, IL-1rn and MMP12) were consistently up regulated
(Additional file 5) indicating differential effects on the IL-
4-regulated anti-inflammatory pathway genes in lung and
liver. In 9 V/null lung, these data show that the IL-4 regu-
lated anti-inflammatory cytokines/mediators were also
temporally and spatially altered and they were expressed
in parallel with coordinate pro-inflammatory genes with
disease progression.
The pro- and anti-inflammatory gene expression pat-
terns were analyzed in the more attenuated 4L model. In
4L lung, the percentage of altered macrophage activation
genes was ~50% of that in 9 V/null lungs (Table 1). No
pro-inflammatory genes were altered in 4L lungs during
disease progression (Table 2), and the immunohistochem-
istry as well as routine histology were identical to WT.
Only three anti-inflammatory genes (CCL17, Igh-6 and
Rentla) were consistently (≥2 time points) up regulated
in 4L lung. The expression patterns of anti-inflammatory
genes in liver of 4L mice were similar to those in the 9
V/null mice. There were no pro-inflammatory genes sig-
nificantly altered and only the anti-inflammatory genes,
Igh-6, IL-1rn, or MMP12, were consistently up regulated
in 9 V/null and 4L liver (Additional file 5). In summary,
the median expression values of pro-inflammatory and
anti-inflammatory genes in 9 V/null lung were 2-fold
higher than that in 9 V/null liver and 4L tissues
(Figure 6). These data demonstrate the differential RNA
expression of pro-inflammatory or anti-inflammatory
cytokines/mediators and their correlation with type of
mutations and tissues, and disease progression. The
results also indicate a differential molecular pathophysiol-
ogy in 9 V/null or 4L Gaucher disease mice that is likely
related to the degree of storage cell infiltration and accu-
mulation of glucosylceramide.
Commonality of significantly expressed genes involved
in macrophage activation
To explore the commonality of affected global or
macrophage activation genes between two tissues in
Gba1 variant mice, comparative analyses were displayed
as Venn diagrams. More than 50% of the altered genes
globally in lung or liver were concordantly and signifi-
cantly expressed in 9 V/null and 4L mice (Figure 7A
and 7B, Additional file 5). These common genes were
distributed in all 12 functional categories. Similar results
were obtained by commonality analysis of significantly
expressed macrophage activation genes between tissues
of both Gba1 mutant models. As shown, ~50% of
macrophage activation genes in lung or liver of 9V/null
mice were similarly affected in 4L mice (Figure 7C and
7D). The intersection of macrophage activation genes in
lung or liver from 9 V/null and 4L mice includes pro-/
anti-inflammatory cytokines, cytokine receptors, growth
Figure 5 Consistently up-regulated macrophage activation
genes in 9 V/null and 4L mice. The expression values of each
consistently (≥2 time points from 12 to 28 wk) up-regulated
macrophage activation genes in the lung (Lu) and liver (Lv) of 9 V/
null and 4L mice were plotted on the ordinate. The mean
expression values (fold-change) of these genes in each tissue are
indicated by a horizontal bar. The numbers of these genes were 96/
119 (81%) or 15/21 (71%) in 9 V/null lung or liver, respectively; and
43/83 (52%) or 14/21 (67%) in 4L lung or liver, respectively
(Additional file 3). The median fold change for these gene
expression values in 9 V/null lung and liver were higher than in the
corresponding 4L tissues.
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the matched macrophage activation genes in the inter-
section were concordantly up or down regulated in both
lung and liver of 9 V/null and 4L mice. These data sug-
gest a common basic pathway of macrophage activation
genes in multiple tissues of Gba1 mutated mice. In the
lung of the 9 V/null and 4L models, all genes for anti-
gen processing related to MHC II and some comple-
ment components were up-regulated (Additional file 5).
The effect of MHC on cytokine production has been
shown to be particularly important in resistance of mice
to intracellular pathogens [19]. These data imply that
GCase deficiency and resultant substrate accumulation
stimulated multiple immune response genes. The above
analyses demonstrate that substantial numbers of
macrophage activation genes were significantly affected
in Gba1 variant mice, most of them were up-regulated
and concordant with the disease progression from 12 to
28 wk, many were shared among tissues, but some were
more tissue specific. Although the molecular cascades in
macrophage activation are not yet known, the tissue-/
mutation-type and disease progress correlated profiles of
macrophage activation-related genes suggest common
temporally and spatially regulated mechanisms in the
pathophysiology of Gaucher disease. The expression
profiles of these genes also indicated macrophage activa-
tion in Gba1 variant mice with significant heterogeneity
between the tissues and mutation types.
Effects of genetic background on mRNA profiles
The genetic backgrounds of 9 V/null (FVB and C57BL/
6J-129SvEvBrd) and 4L (C57BL/6J-129SvEvBrd) were
slightly different, since the 9 V/null was generated by
crosses of 9 V/9 V (C57BL/6J-129SvEvBrd) with null/
WT (FVB) mice. To validate the macrophage gene
expression profile and evaluate effects of the FVB strain
on gene expression, FVB WT data sets (2 chips at 4 dif-
ferent time points each tissue) were run using the same
methods and standards. A total of 48 chip sets (each 8
chip data from 9 V/null lung and liver, 4L lung and
Table 2 Expression of pro- and anti-inflammatory macrophage activation genes in lungs of 9 V/null and 4L mice
9 V/null 4L
Pathways Symbol Gene Name lu_4
wk
lu_12
wk
lu_18
wk
lu_28
wk
lu_4
wk
lu_12
wk
lu_18
wk
lu_28
wk
IFNg
regulated
IFNg* interferon gamma 1.124 1.292 1.336 1.204 1.513 1.278 1.329 1.435
CCL19 chemokine (C-C motif) ligand 19 1.325 3.288 3.336 2.039 1.738 1.469 1.166 1.536
CCL2* chemokine (C-C motif) ligand 2 1.134 2.835 2.564 2.467 1.284 1.220 1.203 1.463
CCL3* chemokine (C-C motif) ligand 3 1.855 19.86 37.518 22.298 1.464 1.673 1.155 1.347
CCL6 chemokine (C-C motif) ligand 6 2.004 4.073 6.557 6.138 -1.380 -1.090 -1.344 1.228
CCL9* chemokine (C-C motif) ligand 9 1.893 5.817 10.346 9.722 1.317 1.546 1.512 1.365
CD44 CD44 antigen 3.176 4.971 2.155 2.387 1.060 1.156 -1.045 1.294
CXCL1 chemokine (C-X-C motif) ligand 1 1.466 8.56 10.786 7.739 1.322 1.252 -1.183 1.663
CXCL12 chemokine (C-X-C motif) ligand 12 2.65 2.991 1.923 1.874 1.679 1.334 1.130 1.030
IL-6* interleukin 6 -1.249 1.189 1.029 -1.009 -1.080 -1.261 -1.262 -1.106
Msr1 macrophage scavenger receptor 1 1.092 2.843 2.808 2.322 1.349 1.515 -1.089 1.076
NOS2* nitric oxide synthase 2, inducible,
macrophage
1.226 1.207 -1.001 1.13 1.206 1.351 -1.001 1.200
TNF* tumor necrosis factor -1.096 1.036 1.279 1.337 1.184 1.384 -1.008 1.451
IL-4 regulated IL-4* interleukin 4 -1.074 -1.007 1.135 1.253 -1.071 1.286 1.107 1.367
Arg2 arginase type II 1.315 2.661 3.044 2.034 1.787 2.179 1.298 1.344
CCL17 chemokine (C-C motif) ligand 17 1.146 3.756 8.523 5.903 1.982 2.494 1.522 1.674
CCL22 chemokine (C-C motif) ligand 22 1.237 3.066 2.734 2.725 1.402 1.477 1.096 1.559
CD163* CD163 antigen -1.029 1.013 -1.446 -1.391 1.173 1.142 1.234 -1.335
Igh-6 Immunoglobulin heavy chain 6 3.036 3.066 3.430 2.565 2.864 1.810 1.724 1.637
IL-1rn interleukin 1 receptor antagonist 1.417 3.615 3.815 2.762 1.296 1.317 1.376 1.141
MMP12* matrix metallopeptidase 12 1.705 37.346 56.278 39.721 1.225 1.023 -1.240 1.217
MMP19 matrix metallopeptidase 19 1.762 3.607 3.428 3.112 1.659 1.650 1.563 -1.249
MMP9 matrix metallopeptidase 9 1.272 2.837 4.307 2.308 -1.353 1.233 1.199 1.226
Retnla resistin like alpha 1.920 2.229 2.480 3.800 2.796 1.538 2.536 1.840
Note: The gene symbols in Bold were not significantly expressed in microarray analysis, but were positive on immunohistochemstry in 9 V/null lung. The
numbers show Fold Change in gene expression. The numbers in Bold were significantly affected and satisfied with FDR (≤0.01) and Fold Change at ≥ ± 1.8.
Genes with * sign were positive on immunohistochemistry. wk = week.
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Page 8 of 23liver, and FVB WT lung and liver) were loaded into Par-
tek Genomics Suite 6.4, and the data were normalized
and analyzed (see Methods). FDR was set at 0.01 and
fold change was set at ±1.8 for significance.
The numbers of significantly expressed genes in 9 V/null
lung based upon the WT controls from these two different
genetic backgrounds are as follows. With the FVB WT as
control data set, 910 genes with significantly altered
expression were selected. Among them, 10% (90/910
genes) were macrophage activation genes and 1.6% (15/
910) were pro-/anti-inflammatory genes (Additional file 6
and Additional file 7 Table S1). The commonality of
macrophage genes selected based upon different genetic
background was also analyzed. Among 90 macrophage
genes (FVB8chip), 52% (47 genes) were the same as with
genetic matched controls (FVB/C57BL/6J-129Svchip). Also,
83% of INFg/IL-4 regulated pathway genes were shown to
have similar gene expression profiles using either of the
two genetic backgrounds. Although some variation exists
in the selected genes and their expression significance, the
macrophage activation genes, including INFg and IL-4
pathway genes, were identified as a major functional group
using either strains.
Validation of selected mRNA expression
The genes identified by microarray analyses were selec-
tively validated by real-time RT-PCR of the same pooled
RNA as used for chip analyses. Primer sets for CCL9,
Figure 6 Time course of expression profiles of pro-inflammatory (A) and anti-inflammatory (B) genes in 9 V/null (white) or 4L (grey)
mice. The box plots of fold change (log2) show the median value of fold change of genes in each group (horizontal bars). The upper and
lower boundaries of the boxes indicate the 75
th and 25
th percentile. The whiskers indicate the minimum and maximum of data set. The median
fold change in the pro-(A) and anti-(B) inflammatory genes of 9 V/null lung showed a steep increase from 4 to 12 to 28 wk that paralleled those
in 9 V/null livers. The expression levels of these same genes in 4L lung and livers were lower and nearly constant over the time course of the
analyses.
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assays and b-actin RNA was used as an internal control.
The results show similar patterns of cytokine
gene expression to those obtained by chip analyses. The
fold-change values obtained with real-time RT-PCR
were 2- to 4-fold higher than those from chip analyses
(Figure 8). This reflects inherent differences of the two
methods.
Immunohistochemical studies of the macrophage
activation related genes
Histological and immunohistochemical studies were
conducted with lung and liver sections from 9 V/null
and 4L mice to correlate gene expression patterns with
protein levels. As shown, numerous large storage cells
were observed in 9 V/null lung with positivity for the
surface antigens, CD68 and F4/80 (Figure 2). CD68
RNA also was elevated in lungs (3.3-7.2 fold) and livers
(2.0-4.8 fold) of 9 V/null mice at 12 to 28 wk, but they
had no significant alteration in 4L lung and liver (Addi-
tional files 1 and 4). This result would be expected
because of the large number of storage cells in the lungs
of 9 V/null mice. Immunohistochemical staining with
CD68 antibody showed high intensity CD68-positive
storage cells in the lung (Figure 2, middle) and liver
(not shown). CD68-positive cells were quantified and
showed 205 and 241 per 20 representative fields (40×)
in the lung from two 9 V/null mice. A few small sized
CD68-positive cells were observed in WT lung at 28 wk
(Figure 2, middle). In 4L lungs, multiple (268 ± 38, 40×
field, n = 10) small CD68-positive macrophages were
present at 28 wk (Figure 2, middle). F4/80 (Emr1) RNA
signals were within ±1.8-fold range in all 9 V/null and
4L tissues. By immunohistochemistry, F4/80 positive
macrophages were 190 and 174 per 20 fields (40×) in
the lung of two 9 V/null mice. The qualitative staining
intensity of F4/80-positive storage cells was weak to
medium compared to that of CD68 positive cells in lung
of 9 V/null mice (Figure 2, bottom).
Macrophage activation in 4L and 9 V/null mice was
evaluated using antibodies to cytokines corresponding
to genes with differential RNA expression. Antibodies
to pro-inflammatory cytokines INFg,I L - 6 ,N O S 2
(Figure 9), CCL2, CCL3, CCL9 (Figure 10), and TNFa
(Figure 11) stained storage cells intensely in lungs from
9 V/null mice and were quantified microscopically (see
below). Some NOS2 positive cells were present in 4L
lungs, but the antibodies to the other cytokines were
negative (Figure 9). The RNA expression level of INFg,
IL-6, NOS2 and TNFa in 9 V/null lungs did not satisfy
the FDR ≤ 0.01, but the respective proteins could be
detected by immunohistochemistry at 12 to 28 wk. By
dual immunofluorescence staining, many TNFa signals
co-localized with CD68 signals in 9 V/null lung; the
TNFa intensity was relatively weak compared with
CD68 signal (Figure 11, merged pictures). TNFa signals
in 4L lung at 12 and 18 wk were also positive, but with
lower intensities and in fewer cells compared with those
in 9 V/null lung at 28 wk (data not shown).
In 9 V/null lungs, positive signals were also evident
for the anti-inflammatory cytokines, IL-4, MMP12, and
Arg2 (Figure 12), and CD163 (Figure 13). As with some
pro-inflammatory genes, the RNA expression of IL-4 or
CD163 genes in 9 V/null lungs did not satisfy the FDR
0.01, but their protein levels were assessed by immuno-
histochemistry or immunofluorescence staining at 12 to
28 wk. The signals of IL-4 positive macrophages were
relatively weak in lung of 9 V/null at 28 wk, and no sig-
nals were detected in WT and 4L lung (Figure 12). The
staining intensity with Arg2 and MMP12 antibody
was at intermediate levels in 9 V/null lung at 28 wk
(Figure 12). Arg2 positive cells also were observed in the
lung of 4L mice at 28 wk. CD163 signals were signifi-
cant in lung of 9 V/null mice compared with the signals
in WT and 4L tissues (Figure 13), and these mostly co-
localized with CD68 signals. In 4L mouse lung, the
macrophages were small. The antibody positive macro-
phages for CCL2, CCL3, CCL9, IL-6, NOS2,I L - 4 ,o r
MMP12 were quantified as above and showed 79 to 122
per 20 fields in 9 V/null lung (Figure 14); INFg or Arg2
antibody positive cells numbered 220 or 190 per 20
fields. The intensity of each antibody staining at 4 to 28
Figure 7 The commonality and uniqueness of significantly
differentially expressed genes (A and B) and macrophage
activation genes (C and D) in lungs (A and C) and livers (B and
D) from 9 V/null and 4L mice. Venn diagrams show the absolute
number of differentially expressed genes in 9 V/null or 4L tissues.
Among the differentially expressed genes, 729 in lung (A) and 217
in liver (B) were common to 9 V/null and 4L mice. In comparison,
the uniquely expressed genes in 9 V/null or 4L lungs were 442 or
646, respectively; and 185 or 189 in 9 V/null or 4L livers. In (C and
D) the Venn diagrams represent the number of differentially
expressed macrophage activation genes in 9 V/null and 4L lungs (C)
and livers (D). Among these genes, 56 in lungs and 13 in livers were
found common to 9 V/null and 4L mice. The numbers of uniquely
expressed genes in 9 V/null or 4L lungs were 63 or 27, respectively;
13 or 11 in 9 V/null or 4L livers. The expression values of these
genes are in Additional file 4.
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sion profile. These studies show differential expression
of macrophage activation related genes in the various
mice with Gba1 mutations that were nearly cell specific.
IFNg and IL-4 regulated pathways and gene expression
networks
PathwayArchitect 2.0.1 (Stratagene, La Jolla, CA) and
Ingenuity Pathways Analysis (Ingenuity Systems, Inc.)
were conducted to summarize the potential interactions
of pro-inflammatory or anti-inflammatory cytokines/
mediators based on the RNA microarray data and
immunohistochemical data (Figure 15). Nine of 13
macrophage pro-inflammatory genes were significantly
affected at 4 wk (Figure 15A, left, red or orange color).
Beginning at 12 wk, all 13 pro-inflammatory genes were
significantly up regulated at the RNA or protein levels,
and then remained at up-regulation until 28 wk
(Figure 15A). Most of anti-inflammatory genes in the 9
V/null lung were not changed at 4 wk (Figure 15B,
white color), but were at 12 to 28 wk (Figure 15B, red
or orange color). Interestingly, the up-regulation of IL-4
was only detected at 28 wk. This pro- or anti-inflamma-
tory pathway model summarizes a significant coordina-
tion and interaction of pro- or anti-inflammatory
cytokines/mediators in the disease process.
A potential global gene expression network and a cas-
cade regulation initiated by macrophage activation genes
were evaluated using PathwayArchitect 2.0.1 and Inge-
nuity Pathways Analysis programs. A total 391 signifi-
cantly expressed genes in 9 V/null and 345 genes in 4L
lungs were connected in the IFNg- or IL-4-regulated
pro-/anti-inflammatory pathway (Figure 16A and 16B).
This network was built with a high confidence index of
direct and indirect interactions. In this cascade network,
IFNg- and IL-4-regulated pro-/anti-inflammatory genes
as core genes (red) connected with many different func-
tional pathways through key genes. These key genes are
significantly connected to the next group genes in the
cascade of network (connectivity >1000) [20]. The
included main gene groups in each cascade regulation
were for transcription (green), kinase activity (blue), cell
Figure 8 RT-PCR verification of selected cytokine gene expression levels. Pooled lung RNA samples used for microarray analyses were used
for RT-PCR of CCL9, Msr1, CCL17, MMP12, and b-actin. Signals for these genes from 9 V/null and WT lung RNAs were normalized to b-actin RNA.
The average values (fold changes) for RT-PCR (hatched bar) represent the ratios of 9 V/null and WT at each time point (X-axis). The fold change
values were from 2 separate triplicate experiments. The comparative fold changes (Table 1) for each respective gene from the microarray
analyses are shown as grey bar.
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Page 11 of 23death (purple), and signal transduction (yellow) (Addi-
tional file 8).
Discussion
The genome-wide transcriptome data presented here
demonstrate genotype and tissue-type related gene
expression patterns in 9 V/null and 4L mice that are
analogues of human Gaucher disease. Interestingly, the
percentage of functional categories containing dysregu-
lated RNAs was similar across all 9 V/null or 4L tissues,
except for the macrophage activation genes that showed
~2-fold enrichment in 9 V/null lung, the most exten-
sively involved organ (Table 1). Another identified
group was that for immune response genes, which were
altered only in 9 V/null lung. Among the 54 immune
response genes, 47 overlapped with the macrophage
group. Since histological analyses did not find obvious
T-cell and B-cell infiltration in 9 V/null lung, these
immune responses likely emanated from macrophages.
Macrophage activation in 9 V/null lung was also
supported by hierarchical clustering analysis in which
the 117 genes in cluster 3 (Figure 3) were exclusively
expressed in 9 V/null, rather than in 4L lung; a third of
these were macrophage activation genes (Figure 3, high-
lighted region). These results indicate significant invol-
vement of macrophage activation genes in 9 V/null
lung, which was concordant with the extensive macro-
phage infiltration in the lungs. Moreover, the comple-
mentary histopathological studies showed that the
nature of macrophage activation was not uniform
between tissues or within macrophages in a specific tis-
sue. These data support the concept of a variety of dys-
regulated macrophages that are tissue and disease state
dependent as a dynamic component of the Gaucher dis-
ease/glucosylceramide storage pathophysiology.
Engorged macrophages are a hallmark of Gaucher dis-
ease, and these cells were differentially activated in tis-
sues of 9 V/null and 4L mice at the mRNA, cellular,
and immunohistochemical levels. The progressively
increasing sizes and numbers of macrophages in visceral
Figure 9 Expression of IFNg and pro-inflammatory cytokines in lung macrophages of WT, 4L, and 9 V/null mice. Lung sections were
from 28-wk age-matched mice. Large storage cells in 9 V/null lungs were positive for IFNg, IL-6, and NOS2 (arrows). In 4L lung, a few, small
NOS2 signal positive cells present (arrows). WT lungs did not exhibit positive staining. The scale bars are 20 μm. Magnification = 400×.
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rage, was particularly evident in lungs of 9 V/null mice
from 12 to 28 wk (Figure 1). Immunohistochemistry
with the antibodies to selected IFNg-regulated pro-
inflammatory and IL-4-regulated anti-inflammatory
cytokines showed that these cytokines were expressed in
lung macrophages, but not in lung epithelial cells, i.e.,
there were pro- and anti-inflammatory responses (or
activation) of the lipid-laden macrophage. Also, such
analyses showed significant expression of the IFNg pro-
tein in lung macrophages of 9 V/null mice at 12 and
28 wk (Figure 9), but lesser expression in liver. These
expression patterns were concordant with the differen-
tial activation of macrophages in these tissues as was
evident by both microarray and morphologic data. In
addition, IFNg and its regulated pathway genes were less
aberrant in tissues of the 4L mice, a more attenuated
model, as ascertained by RNA or protein analyses.
These results implicate pro-inflammation as a primary
pathophysiological mechanism in Gaucher disease, as
well as the degree of alterations in this pathway in the
severity of Gaucher disease involvement. The production
and secretion of cytokines from storage macrophages
can be the important factors for the extracellular matrix
components and function as they influence the interac-
tion of surrounding macrophages with phagocytotic or
endocytotic ligands and propagate the pathophysiology
[21].
IFNg is a potent activator of macrophages and induces
the expression of >300 genes, including those in the
inflammatory mediator/chemokine pathway [22]. Also,
activated macrophages can be a significant source of
IFNg [23-25]. Importantly, IFNg inhibits macrophage
proliferation and protects them from apoptosis [26],
thereby prolonging their survival within inflammatory
loci [27]. Here, the RNA expression levels of IFNg,I L - 6 ,
NOS2, and TNFa were not significantly increased
(FDR = 0.01), but their protein levels were specifically
Figure 10 Expression of CCL2, 3, and 9 in lung macrophages of WT, 4L and 9 V/null mice. Lung sections from WT (left), 4L (middle) and 9
V/null (right) mice at the age of 28-wk were the same as in Figure 2 and 9. Abundant large storage cells in 9 V/null lungs were positive for
CCL2, CCL3, and CCL9 (e.g., arrows). 4L and WT lungs were negative. The scale bars are 20 μm. Magnification = 400x.
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This observation indicates that the expression of these
proteins and RNAs could be missed in whole tissue
homogenates in which there may be large dilutional
effects, if expression is restricted to specific cell types
that make up a small percentage of total cells, e.g.,
macrophages. Importantly, 12 other cytokines are in the
IFNg pathway and could be downstream modulated by
this cytokine. For example, IFNg can induce TNFa and
NOS2, and has differential effects on several individual
chemokine genes [8] that provide for selective stimulus
sensitivity in mediating restricted pattern of chemokine
gene expression. Transcripts for CXCL1/12 and the
CCL chemokines (CCL2, 3, 6, 9 or 19) can be enhanced
by Th1-related inflammatory mediators including IFNg,
IL-6, TNFa, or LPS [28,29] as well as modulating the
effects of each other (Figure 15). The outcomes of such
interactions lead to a cascading cytokine pro-inflamma-
tory dysregulation that propagates Gaucher disease.
Indeed, TNFa is a major regulator of chemokine gene
expression, e.g., CXCL2, CCL3 and IL-6 [30-37]. The
finding here that TNFa protein was up regulated (Figure
11) implicates its downstreamc y t o k i n en e t w o r kd u r i n g
Gaucher disease progression. Also, cytokines, e.g., CCL3,
act synergistically with other macrophage chemokines
[38] to maintain the pro-inflammatory reactions.
Pro-inflammatory cytokin e sp l a yac r i t i c a lr o l ei n
macrophage/leukocyte recruitment and adhesion [39-42]
and they recruit new macrophages to involved tissues
via this cytokine network. Under the stimulus of accu-
mulating glucosylceramide and other glucolipids, such a
positive feedback macrophage-cytokine-macrophage
cycle can be envisioned to expand and promote progres-
sion and the recruitment of additional pro-inflammatory
cytokines/mediators networks (Figure 15). The progres-
sive cascade is schematically shown in Figure 15
in which numerous interacting cytokines and chemo-
kines are progressively up-regulated during disease
Figure 11 Expression of TNFa and colocalization with CD68 in lung macrophages from WT, 4L, and 9 V/null mice. Anti-CD68 is green
(FITC) and anti-TNFa is red (Alexa-610). Abundant large storage cells in 9 V/null lungs were CD68 or TNFa positive (e.g., arrows). 4L and WT
lungs showed a few scattered small positive cells but none appeared to be positive for both antibodies. TNFa and CD68 colocalized in many of
9 V/null macrophages (yellow). The scale bars are 20 μm. Magnification = 400×.
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cading network with initial mRNA up-regulation of
b- and a-chemokines, as well as Mrs1 (macrophage sca-
venger receptor 1), TNFa,a n dN O S 2 .A m o n gt h e s e
interacting factors is the pleiotropic cytokine IL-6,
which is a systemic alarm for tissue damage [43-45].
The b-chemokines, CCL2, CCL3, CCL6, CCL9, CCL19,
and the a-chemokines, CXCL1, CXCL12, mediate pro-
inflammatory effects in the various types of cells and
also have synergetic effects on their targets [30,33,46].
The macrophage scavenger receptor 1 (Msr1) has been
implicated in many macrophage-associated physiological
and pathological processes through endocytosis [47].
NOS2 and arginase were up-regulated at the RNA and
protein levels in the 9 V/null mice, and as has been
observed in ex vivo studies [48]. NOS2 produces nitric
oxide from arginine and stimulates pro-inflammation
[49-51]. NOS2 production in macrophages up-regulates
vascular endothelial growth factor (e.g. VEGF) produc-
tion and activates angiogenic activity [52,53]. In
comparison, arginase2 is a negative angiogenic regulator
that inhibits NOS2 activity [54]. Thus, arginase2 and
NOS2 alternative pathways in activated macrophages
[24] and their up-regulation in 9 V/null mice simulta-
neous pro- and anti-inflammatory networks are being
activated in the Gaucher disease process.
Interrogation of the IL-4 mediated anti-inflammatory
network highlights significantly differential expression of
11 anti-inflammatory genes, indicating that participation
of the aam IL-4 pathway that counteract expression of
macrophage pro-inflammatory cytokines and induce
molecules that facilitate tolerance, healing and ex-
pression of innate immunity receptors, e.g. the scaven-
ger receptor, CD163 [7,55,56]. The IL-4 pathway
(Figure 15B) displays the IL-4 time course and interac-
tions over the 4 to 28 wk period. After an initial lag per-
iod from 4 to 12 wk, a network of such Th2 response
genes [57,58] is up-regulated at the RNA and/or protein
levels. This network includes the structurally and func-
tionally related matrix metalloproteinases MMP9/12/19
Figure 12 Expression of IL-4, MMP12 and Arg2 in lung macrophages from WT, 4L, and 9 V/null mice. Lung sections were as in Figure 2,
9, 10 and 11. Large storage cells in 9 V/null lungs were positive for IL-4, MMP12, and Arg2 (e.g., arrows), whereas only a few were in 4L lungs.
WT lungs were negative. The scale bars are 20 μm. Magnification = 400×.
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Page 15 of 23Figure 13 Expression of the scavenger receptor, CD163, and CD68 in lung macrophages from WT, 4L, and 9 V/null mice. Anti-CD68 is
green (FITC) and anti-CD163 is red (Alexa-610). The colocalization (yellow) of CD163 signals with CD68 in 9 V/null lungs showed about half the
storage cells were double positive and no cells staining only with CD163. Some low level signals for CD68 and CD163 were seen in small cells in
4L lungs. The scale bars are 20 μm. Magnification = 400×.
Figure 14 Heterogeneity of cytokine expression in lung macrophages of 9 V/null mice. The pro-/anti-inflammatory cytokine antibody
stained lung sections from 9 V/null mice of 28-wk (Figure 9, 10 and 12) were analyzed (20 serial fields at 400×). The antibody positive
macrophages were quantified in each field, and plotted (Y-axis) for each cytokine protein (X-axis). The numbers below each column are the
respective antibody positive macrophages counts.
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cesses [9,17,59,60]. These MMPs are among the most
highly-expressed genes in most 9 V/null tissues.
The high level expression of MMPs correlated with
chronic fibrotic processes in 9 V/null lung and liver
(unpublished observation). MMP12 expression occurs in
human alveolar macrophages [18,61] and airway smooth
muscle cells [62], and in murine alveolar type II epithe-
lial cells [63] or primary lung fibroblasts [64]. The
immunohistochemistry showed very strong signals in
Figure 15 Time course changes in cytokine network pathways of lungs from 9 V/null mice. Thirteen pro-inflammatory (A) and eleven anti-
inflammatory (B) genes were differentially regulated in lungs of 9 V/null mice across the 4 to 28 wk period. IFNg-regulated pro- or IL-4-regulated
anti-inflammatory genes were selected using Ingenuity Pathway Analysis and the pathways were built using PathwayArchitect 2.0.1. Expression
levels of pro- or anti-inflammatory genes are represented by color: red ≥ 1.8 fold change; white within ±1.8 fold change. The connecting lines
between genes indicate interactions. The expression of IFNg, IL-6, NOS2, TNFa, IL-4 and CD163 did not meet the statistical significance, but did
have antibody positivity. Theses are designated as: weak (orange), medium (purple), or high (red) immunohistological signals.
Figure 16 Global gene expression network profiles. In 9 V/null lung 391 genes (A) and in 4L lung 345 genes (B) were analyzed as a cascade
network using PathwayArchitect 2.0.1 and Ingenuity Pathways Analysis programs. These genes had a high confidence index of direct and
indirect interaction with IFNg/IL-4 macrophage activation genes, which function as core genes (red) and connect to the cascade network via key
genes. Gene interactions are shown by the connecting lines. The key genes are those that can be connected to multiple genes. The major key
genes are highlighted with different colors for macrophage activation (red), transcription (green), kinase activity (blue), cell death (purple), and
signal transduction (yellow) (Additional file 8).
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in other lung cells (Figure 12). The extremely high level
of MMP12 expression (37 to 56-fold in 9 V/null lung
and 16 to 22-fold in 9 V/null liver) implicates the aam
in Gaucher disease progression.
The aams are also implicated in the disease progres-
sion in 9 V/null mice as evidenced by CD163 expression
[10,65] and, particularly, expression of the IL-1 receptor
antagonist (IL-1rn). IL-1rn inhibits the activities of IL-1A
and IL-1B, and modulates IL-1 related immune and
inflammatory responses. IL-1rn is typically produced by
aam and regulated by IL-4 [66,67]. The interactions of
these anti-inflammatory cytokines are schematically
shown in Figure 15 and indicate an overall description of
pro-/anti-inflammatory networks in Gba1 mutant mice.
The global gene expression networks integrate the
gene expression patterns observed in 9 V/null or 4L
mice. In these networks, more than 1/3 of significantly
expressed genes were connected through the cascade
interactions of pro- and anti-inflammatory genes.
Although the macrophage involvement is major histo-
pathological finding, about 3% of the genome was signif-
icantly altered at a molecular level during the
development of the disease process. The propagation of
the disease clearly depends on a generalized pro- and
anti-inflammatory disruption.
Macrophages display marked phenotype heterogeneity
in vitro and in vivo, including the responsiveness to
endogenous and exogenous stimuli [8]. Such heteroge-
neity results in differential phagocytosis or endocytosis,
intracellular signaling and gene activation or repression
[21,68]. Macrophage heterogeneity was observed in the
9 V/null and 4L models by their differential activation
and tissue distribution. Large lipid-laden macrophages
( C D 6 8a n dF 4 / 8 0p o s i t i v e )w e r em o s t l yo b s e r v e di nt h e
lung of 9 V/null mice. Quantitative immunohistochem-
i s t r ys h o w e do n l ys o m ec y t o k i n e s / e f f e c t o r s( i . e . ,I L - 6 ,
NOS2, CCL2, CCL3, CCL9, IL-4, and MMP12) were
present in ~50% of lung macrophages (Figure 14). How-
ever, IFNg and Arg2 were present in nearly all of such
macrophages. The corresponding RNAs of the cytokine/
effectors were also up regulated. The basis for this het-
erogeneous expression of cytokine proteins in macro-
phages is unknown, but may be due to the different
origins, differentiation sates, or maturation of the
macrophage populations.
The genetic background of mice can influence gene
expression profiles. Interstrain variations (1-3%) of gene
expression profiles have bee ns h o w ni nd i f f e r e n tb r a i n
regions of mouse inbred strains [69-72]. For example,
such variation can be observed in the differential sus-
ceptibility to a wide range of pathogens [73-76]. Here, 9
V/null and 4L mice had mixed strain backgrounds from
three in-bred mouse strains FVB and/or C57BL/6J-
129Sv. To evaluate the potential effects of mouse strain
background on the expression profiles of macrophage
activation genes, the WT data sets from FVB and three
inbred mixed strains were used in the analyses. The
result showed >50% of significantly expressed macro-
phage activation genes were shared when either of the
two background controls were used. There was 83%
concordance in the INFg- and IL-4- regulated pathway
genes. In addition, comparative analyses were conducted
with duplicate lung RNA chip data from WT adult mice
of three different genetic backgrounds (FVB, C57BL/6J,
or 129Sv). The combined WT data generated 790 signif-
icantly expressed genes in 9 V/null lung (data not
shown). About 60% of significantly expressed macro-
phage genes were concordant between FVB only or
strain-matched WT controls, including >90% of INFg-/
IL4-regulated pathway genes (data not shown). The
results showed general agreement of the gene expression
profiles from individual WT backgrounds with those
from WT controls either pure FVB or strain-matched
backgrounds. The results show that macrophage activa-
tion genes are a significant functional group in the
propagation of Gaucher disease in several genetic
backgrounds.
Conclusions
We demonstrated direct relationships between the
degree of tissue glucosylceramides and the gene expres-
sion profile alterations. These analyses implicate IFNg-
regulated pro-inflammatory and IL-4-regulated anti-
inflammatory networks in differential disease progres-
sion with implications for understanding the Gaucher
disease course and pathophysiology.
Methods
Materials
The following were from commercial sources: RNA
Later and TOTALLY RNA kit (Ambion, Austin, TX).
Antibody sources are as the follows: Anti-INFg,C C L 2 ,
CCL3, CCL9, CD68, F4/80, IL-4, CD68, and Goat anti-
rat-HRP (Serotec, Raleigh, NC). Anti-TNFa (Biosource,
Camarillo, CA). Anti-Arg1, Arg2 and CD163 (Santa
Cruz, CA). Anti-NOS2 (Chemicon, Temecula, CA),
A n t i - I L 6( R&D ,M i n n e a p o l i s ,M N ) .A n t i - M M P 1 2
(Biomol, Plymouth Meeting, PA). Horse anti-goat-
HRP, ABC Vectastain and DAB Substrate Kit (Vector
l a b o r a t o r y ,B u r l i n g a m e ,C A ) .S h e e pa n t i - m o u s e - H R P ,
Streptavidin-Alexa Fluor 488, Goat anti-rabbit Alexa
Flour610, Goat anti-rabbit-HRP (Molecular Probes,
Irvine, CA). High Capacity cDNA Archive Kit and
SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA).
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V394L/V394L homozygote (4L) and D409V/null mice (9
V/null) were generated with mixed genetic backgrounds.
4L mice were 50% of C57BL/6J and129SvEvBrd and
9 V/null mice were 50% of FVB, 25% of C57BL/6J
and129SvEvBrd [16]. The wild-type (WT) controls were
strain genetic background matched adult mice (50% of
FVB, 25% of C57BL/6J and129SvEvBrd,). All mice were
housed under pathogen-free conditions in the barrier
animal facility and according to IACUC standard proce-
dures at Cincinnati Children’s Hospital Research
Foundation.
Glycosphingolipid analyses
Glycosphingolipids in liver and lung from Gba1 mutant
and WT mice (5 mg tissues) were extracted with chloro-
form and methanol as described [77]. Glucosylceramide
analysis was carried out by ESI-LC-MS/MS using a
Waters Quattro Micro API triple quadrupole mass spec-
trometer (Milford, MA) interfaced with Acquity UPLC
system. The ESI-MS/MS was operated in the multiple
reaction monitoring mode for monitoring transition pair
of the individual protonated parent ions and their com-
mon daughter ion m/z 264. Calibration curves were
built for C16, C18 and C24:1 b-glucosylceramides using
C12 b-glucosylceramide as an internal standard
(Matreya, LLC and Avanti Polar lipids, Inc.). The
extracted glycosphingolipid samples were suspended in
methanol containing internal standard and injected (10
μL) into the LC/MS. The level of total glucosylceramide
in the liver and lung were normalized to mg tissue
weight.
RNA preparation and microarray hybridization
Lungs and livers were collected from 9 V/null and 4L
mice at the age of 4, 12, 18 and 28 wk, and from genetic
background matched adult WT mice (28 wk) and age-
matched FVB WT mice (4 - 28 wk) for total RNA pre-
paration. Collected tissues were immediately immersed
in RNA Later and tissue RNAs were extracted using the
TOTALLY RNA kit. Each tissue RNA set for microarray
analysis was pooled from 3 age and genotype matched
mice and at least duplicate sample sets for each geno-
type, tissue, and age were used. This represents 39
labeled RNA sample sets (4 WT, 8 9 V/null and 8 4L
l u n gR N A s ;3W T ,89V / n u l la n d84 Ll i v e rR N A s )
were submitted to the CCHRF Affymetrix Microarray
Core for hybridization to Affymetrix GeneChip Mouse
Genome 430 2.0 Arrays using standardized protocols.
Labeled cRNA synthesis, GeneChip hybridization, wash-
ing and staining followed standard Affymetrix protocols.
The probed arrays were scanned with the Affymetrix
GeneChip
® Scanner 3000 and the intensities of array sig-
nals were captured with GeneChip Operating Software
(GCOS) v1.1.0, according to standard Affymetrix
procedures. The entire microarray data set is available at
the Gene Expression Omnibus (GEO) accessible through
GEO series accession number GSE23408.
GeneChip quality assessment
Array data were evaluated for quality assessment using
the procedures in the Affymetrix based on scaling factor
(10-50), percent present (>30%), and housekeeping gene
yielding 3’/5’ signal ratios <3. Global normalization for
outliers or “bad chips” was conducted with each sample/
chip. The normalized intensity values were subjected to
hierarchical clustering to determine the relative signal
intensity of tissue RNA samples derived from different
developmental stages and to identify the outlier(s) or
bad chips. GeneChips that passed these screenings were
used for subsequent analyses to identify significantly
affected genes in tissues of 4L and 9 V/null mice at var-
ious time points. To evaluate the affects of strain or
genetic background, additional control chip data were
from age-matched WT FVB mice (4 to 28 wk, 2 chips
for each age group).
Microarray data normalization and analysis
The chip data for each mouse variant and corresponding
WT controls with 2 tissue types and 4 different time
points were loaded into Partek Genomics Suite 6.4 (Par-
tek, Inc., St Louis, MO) and normalized using the RMA
(robust multiarray average) algorithm [78]. Sample rela-
tionships were examined using principal components
analyses that revealed no strong technical effects, which
may encumber the subsequent analyses. To identify
expression changes between genotypes, a mixed-model
ANOVA was performed and chosen to partition subject,
tissue, age, and genotype. The following linear mixed
model (equation) was generated to detect differential
expression on a gene-by-gene basis:
YG T A G T A S ijkm i j k ijk m ijkm =+ + + ++ ε
Here yijkm is the expression of the gene for ith geno-
type, jth tissue, and kth age, and mth subject. The sym-
bols G, T, A, GTA and S represent effects due to
genotype (G), tissue (T), age (A), genotype-by-tissue-by-
age interaction (GTA), and subject (S). The error for
each gene for sample ijk is designated εijkm.G e n o -
type, tissue, and age are fixed effects, and subject is a
random effect in the mixed model. For each compari-
s o n ,al i n e a rc o n t r a s tw a ss e tu pt oo b t a i nt h er e l a t i v e
fold changes between each mutant and WT control for
each tissue at all time points. Four contrasts were added
in the computation: 9 V/null vs. control and 4L vs. con-
trol in lung and liver. False Discovery Rate (FDR) was
used to further guard against false positives because of
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change was set at ±1.8.
Functional classification
Significantly affected or differentially expressed genes
were subjected to an intensive search to identify biologi-
cal functions. Functional classifications were performed
using the Gene Ontology classification obtained through
the DAVID Bioinformatics Database (available at http://
david.abcc.ncifcrf.gov/home.jsp), and public information
and/or literature references. The enriched functional
categories were determined by Fisher Exact Test using
the corresponding murine genome as a reference data-
set. The significance was set at p-value < 0.05. The dif-
ferentially expressed genes were grouped into the
following categories (Table 1): catalytic activity, cell
death, cytoskeleton, immune response, intracellular sig-
naling cascade, kinase activity, lipid metabolic process,
lysosome, macrophage activation, response to stress,
transcription and transport.
Clustering of gene expression profiles
Hierarchical cluster analysis of the significantly
expressed genes was performed using GeneSpring GX
7.3 (Agilent Technologies, Inc., Santa Clara, CA), which
showed the correlated groups of genes and their expres-
sion patterns across all time points.
Network and Pathway analysis
The significantly differentially expressed genes in the
lung of 9 V/null or 4L were loaded into PathwayArchi-
tect 2.0.1 (Stratagene, La Jolla, CA) and built into IFNg-
or IL-4- regulated pathways and global networks. The
pathways and networks were constructed based upon
the published literature, Ingenuity Pathways Analysis
(Ingenuity Systems, Inc), and PathwayArchitect 2.0.1
(Stratagene, La Jolla, CA).
Common genes selection
The common differentially expressed genes and consis-
tently expressed macrophage activation genes in the
lung or liver between 9 V/null and 4L mice were dis-
played as Venn diagrams.
Real-time RT-PCR
To verify selected targets from the RNA chip data, real-
time RT-PCR assays were developed. RNAs (10 μg)
from the same pooled samples as used for microarray
chip analyses were used for real-time RT-PCR assays.
Each RNA sample was reverse-transcribed (RT) using
High Capacity cDNA Archive Kit to synthesize total
RNA-cDNA templates with random hexamers. Real-
time RT-PCR was conducted using SYBR Green PCR
Master Mix with sequence specific primers for CCL9,
Msr1, CCL17, MMP12, and b-actin cDNA (Additional
file 7 Table S2). The reaction mixtures were incubated
in ABI/Prism7000 Sequence Detection System for 40
cycles (95°C, 15 sec and 60°C, 20 sec). The primers were
designed with Primer Expression 2.0 (Applied Biosys-
tems) and spanned exon/exon conjunctions (Additional
file Table S2). The real-time RT-PCR signals from each
RNA primer set were normalized by b-actin signals.
Histological studies
Mouse tissues (liver and lung) were collected and fixed
in 10% buffered formalin for hematoxylin and eosin
(H&E) staining and light microscopic studies. For
immunohistochemistry and immunofluorescence stain-
ing, tissues were fixed in 4% paraformaldehyde/phos-
phate buffered saline (PBS), pH 7.4, and processed for
frozen sections. Tissue sections were blocked with 5%
nonfat milk containing 0.4% Triton X-100 in PBS. Tis-
sue sections were incubated with primary anti-mouse
cytokine antibodies at 4°C overnight, and then with the
compatible secondary antibodies at room temperature
(1 h). The secondary antibodies were conjugated with
fluorescene or horseradish peroxidase (HRP), or a bioti-
nylated secondary antibody/streptavidin-dye system was
used. CD68 (FITC) was used as a macrophage marker,
and cytokines were detected using specific antibodies
and biotin/streptavidin-conjugated dye Alexa Fluor-610.
Positively stained macrophages were quantified using a
series of 20 frames (magnification 400x) and counted
using MetaMorph 6.1 (Universal Imaging Corp, Down-
ingtown, PA).
Additional material
Additional file 1: Differentially expressed genes in the lungs and
livers of 9 V/null and 4L mice. Listed significantly differentially
expressed genes in the lungs and livers of Gaucher mouse models D409
V/null (9 V/null) and V394L (4L).
Additional file 2: Classification of differentially expressed genes in
the lungs and livers of 9 V/null and 4L mice. Listed functional
classification of differentially expressed genes in the lungs and livers of 9
V/null and 4L mice.
Additional file 3: Differentially expressed genes in 9 V/null lungs
(cluster 1 in Figure 1). Listed differentially expressed genes and their
functional classification in the lungs of 9 V/null mice (cluster 1 in Figure 1).
Additional file 4: Consistently and significantly expressed
macrophage activation genes in 9 V/null and 4L tissues. Listed up-/
down-regulated and consistently expressed macrophage activation
genes in the lungs and livers of 9 V/null and 4L mice.
Additional file 5: Common and unique macrophage activation
genes in 9 V/null and 4L tissues. Listed common and unique
macrophage activation genes in the lungs or livers between 9 V/null and
4L mice.
Additional file 6: Differentially expressed genes in 9 V/null lung vs.
WT with various backgrounds. Listed differentially expressed global
genes and macrophage activation genes and their commonality in 9 V/
null lungs vs. WT with various backgrounds.
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Page 20 of 23Additional file 7: Table S1. The effect of WT mouse strain background
on the gene expression profiles Analysis of altered genes in 9 V/null lung
against the different wild type (WT) backgrounds: FVB/129Sv/C57BL6J
mix or FVB WT. Table S2. Primers for real-time RT-PCR. Listed the primers
for real-time RT-PCR analyses.
Additional file 8: Differentially expressed genes in network in 9 V/
null and 4L lungs. Listed differentially expressed genes in network and
their functional classification in 9 V/null and 4L lungs.
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